Ceapro Inc V.CZO

Chemicals Specialty Chemicals

Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human, and animal health industries using technology, natural, renewable resources, and developing products, technologies, and delivery systems. The Company's products include a commercial line of natural active ingredients, including beta glucan, avenanthramides (colloidal oat extract), oat powder, oat oil, oat peptides, and lupin peptides, a commercial line of natural anti-aging skincare products, utilizing active ingredients, including beta glucan and avenanthramides and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner.

TSXV:CZO - Post by User

Ceapro Inc

<< Previous

Bullboard Posts

Next >>

Post by prophetoffactzon Sep 10, 2023 9:05am

119 Views

Post# 35628134

Avenanthramide and Alzheimer's, and Parkinson's, etc.

If CZO"s avenanthramide clinical trial promises a strong safety/tolerability profile in the next nine months there are many potential applications. Here's an August plublication talking about neurodegenerative disease. It could make for an interesting licensing deal with milestone payments for different disease categories on the way to potential royalties.

"...our review emphasizes the potential of using Avns as a therapeutic strategy for NDDs and warrants further investigation and clinical exploration."

Overview on the Polyphenol Avenanthramide in Oats ( Avena sativa Linn.) as Regulators of PI3K Signaling in the Management of Neurodegenerative Diseases - PubMed (nih.gov)
Neurodegenerative diseases (NDDs), characterized by the progressive degeneration of neurons, present a significant global health burden with limited therapeutic options. The phosphoinositide 3-kinase (PI3K) signaling pathway plays a crucial role in cell survival, growth, and metabolism, making it an attractive target for therapeutic intervention. The dysregulation of PI3K signaling has been implicated in the pathogenesis of various NDDs including Alzheimer's and Parkinson's disease. Avns have been shown to modulate PI3K/AKT signaling, leading to increased neuronal survival, reduced oxidative stress, and improved cognitive function. This review explores the potential of Avn polyphenols as modulators of the PI3K signaling pathway, focusing on their beneficial effects against NDDs.

<< Previous

Bullboard Posts

Next >>

Morning Market Outlook for Nov. 14, 2024